- Home
- INZY vs BEAT Comparison
INZY vs BEAT Comparison
Compare INZY & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- BEAT
- Stock Information
- Founded
- INZY 2015
- BEAT 2015
- Country
- INZY United States
- BEAT United States
- Employees
- INZY N/A
- BEAT N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- INZY Health Care
- BEAT Technology
- Exchange
- INZY Nasdaq
- BEAT Nasdaq
- Market Cap
- INZY 64.9M
- BEAT 55.6M
- IPO Year
- INZY 2020
- BEAT 2021
- Fundamental
- Price
- INZY $0.92
- BEAT $1.62
- Analyst Decision
- INZY Strong Buy
- BEAT Buy
- Analyst Count
- INZY 9
- BEAT 1
- Target Price
- INZY $17.22
- BEAT $8.00
- AVG Volume (30 Days)
- INZY 453.8K
- BEAT 63.1K
- Earning Date
- INZY 05-06-2025
- BEAT 05-08-2025
- Dividend Yield
- INZY N/A
- BEAT N/A
- EPS Growth
- INZY N/A
- BEAT N/A
- EPS
- INZY N/A
- BEAT N/A
- Revenue
- INZY N/A
- BEAT N/A
- Revenue This Year
- INZY N/A
- BEAT N/A
- Revenue Next Year
- INZY N/A
- BEAT N/A
- P/E Ratio
- INZY N/A
- BEAT N/A
- Revenue Growth
- INZY N/A
- BEAT N/A
- 52 Week Low
- INZY $0.72
- BEAT $1.45
- 52 Week High
- INZY $6.24
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- INZY 44.29
- BEAT 32.29
- Support Level
- INZY $0.83
- BEAT $1.57
- Resistance Level
- INZY $1.08
- BEAT $1.74
- Average True Range (ATR)
- INZY 0.11
- BEAT 0.14
- MACD
- INZY 0.02
- BEAT -0.01
- Stochastic Oscillator
- INZY 55.43
- BEAT 29.17
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.